For almost 50 years, the fractionation of human plasma has been the sole possible source of a wide range of therapeutic proteins--such as coagulation factors, anticoagulants, immunoglobulins, and albumin--essential to the treatment of serious congenital or acquired bleeding or immunological diseases. In the last 20 years, the application of recombinant technologies to mammalian cell cultures has made possible--although with some limitations in productivity, costs, and immunogenic risks-

Scope of the Report:

The global Recombinant Plasma Proteins market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Recombinant Plasma Proteins.

Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.

This report studies the Recombinant Plasma Proteins market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Recombinant Plasma Proteins market by product type and applications/end industries.

Market Segment by Companies, this report covers

CSL Limited

Shire (Takeda Pharmaceutical Company Limited)

Octapharma

Novo Nordisk

Bayer

Bioverativ Therapeutics, Inc. (Sanofi)

Aptevo Therapeutics

Pharming Group

Pfizer

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Chinese Hamster Ovary (CHO) Cell Line

Baby Hamster Kidney (BHK) Cell Line

Human Embryonic Kidney (HEK) Cell Line

Others

Market Segment by Applications, can be divided into

Hemophilia A

Hemophilia B

Von Willebrand Disease

Others

Table of Contents

1 Recombinant Plasma Proteins Market Overview

1.1 Product Overview and Scope of Recombinant Plasma Proteins

1.2 Classification of Recombinant Plasma Proteins by Types

1.2.1 Global Recombinant Plasma Proteins Revenue Comparison by Types (2019-2024)

1.2.2 Global Recombinant Plasma Proteins Revenue Market Share by Types in 2018

1.2.3 Chinese Hamster Ovary (CHO) Cell Line

1.2.4 Baby Hamster Kidney (BHK) Cell Line

1.2.5 Human Embryonic Kidney (HEK) Cell Line

1.2.6 Others

1.3 Global Recombinant Plasma Proteins Market by Application

1.3.1 Global Recombinant Plasma Proteins Market Size and Market Share Comparison by Applications (2014-2024)

1.3.2 Hemophilia A

1.3.3 Hemophilia B

1.3.4 Von Willebrand Disease

1.3.5 Others

1.4 Global Recombinant Plasma Proteins Market by Regions

1.4.1 Global Recombinant Plasma Proteins Market Size (Million USD) Comparison by Regions (2014-2024)

1.4.1 North America (USA, Canada and Mexico) Recombinant Plasma Proteins Status and Prospect (2014-2024)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Recombinant Plasma Proteins Status and Prospect (2014-2024)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Recombinant Plasma Proteins Status and Prospect (2014-2024)

1.4.4 South America (Brazil, Argentina, Colombia) Recombinant Plasma Proteins Status and Prospect (2014-2024)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Recombinant Plasma Proteins Status and Prospect (2014-2024)

1.5 Global Market Size of Recombinant Plasma Proteins (2014-2024)

2 Manufacturers Profiles

2.1 CSL Limited

2.1.1 Business Overview

2.1.2 Recombinant Plasma Proteins Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 CSL Limited Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.2 Shire (Takeda Pharmaceutical Company Limited)

2.2.1 Business Overview

2.2.2 Recombinant Plasma Proteins Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Shire (Takeda Pharmaceutical Company Limited) Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.3 Octapharma

2.3.1 Business Overview

2.3.2 Recombinant Plasma Proteins Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Octapharma Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.4 Novo Nordisk

2.4.1 Business Overview

2.4.2 Recombinant Plasma Proteins Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Novo Nordisk Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.5 Bayer

2.5.1 Business Overview

2.5.2 Recombinant Plasma Proteins Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Bayer Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.6 Bioverativ Therapeutics, Inc. (Sanofi)

2.6.1 Business Overview

2.6.2 Recombinant Plasma Proteins Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Bioverativ Therapeutics, Inc. (Sanofi) Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.7 Aptevo Therapeutics

2.7.1 Business Overview

2.7.2 Recombinant Plasma Proteins Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Aptevo Therapeutics Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.8 Pharming Group

2.8.1 Business Overview

2.8.2 Recombinant Plasma Proteins Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Pharming Group Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

2.9 Pfizer

2.9.1 Business Overview

2.9.2 Recombinant Plasma Proteins Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 Pfizer Recombinant Plasma Proteins Revenue, Gross Margin and Market Share (2017-2018)

3 Global Recombinant Plasma Proteins Market Competition, by Players

3.1 Global Recombinant Plasma Proteins Revenue and Share by Players (2014-2019)

3.2 Market Concentration Rate

3.2.1 Top 5 Recombinant Plasma Proteins Players Market Share

3.2.2 Top 10 Recombinant Plasma Proteins Players Market Share

3.3 Market Competition Trend

4 Global Recombinant Plasma Proteins Market Size by Regions

4.1 Global Recombinant Plasma Proteins Revenue and Market Share by Regions

4.2 North America Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

4.3 Europe Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

4.4 Asia-Pacific Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

4.5 South America Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

4.6 Middle East and Africa Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

5 North America Recombinant Plasma Proteins Revenue by Countries

5.1 North America Recombinant Plasma Proteins Revenue by Countries (2014-2019)

5.2 USA Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

5.3 Canada Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

5.4 Mexico Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

6 Europe Recombinant Plasma Proteins Revenue by Countries

6.1 Europe Recombinant Plasma Proteins Revenue by Countries (2014-2019)

6.2 Germany Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

6.3 UK Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

6.4 France Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

6.5 Russia Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

6.6 Italy Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

7 Asia-Pacific Recombinant Plasma Proteins Revenue by Countries

7.1 Asia-Pacific Recombinant Plasma Proteins Revenue by Countries (2014-2019)

7.2 China Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

7.3 Japan Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

7.4 Korea Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

7.5 India Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

7.6 Southeast Asia Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

8 South America Recombinant Plasma Proteins Revenue by Countries

8.1 South America Recombinant Plasma Proteins Revenue by Countries (2014-2019)

8.2 Brazil Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

8.3 Argentina Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

8.4 Colombia Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

9 Middle East and Africa Revenue Recombinant Plasma Proteins by Countries

9.1 Middle East and Africa Recombinant Plasma Proteins Revenue by Countries (2014-2019)

9.2 Saudi Arabia Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

9.3 UAE Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

9.4 Egypt Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

9.5 Nigeria Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

9.6 South Africa Recombinant Plasma Proteins Revenue and Growth Rate (2014-2019)

10 Global Recombinant Plasma Proteins Market Segment by Type

10.1 Global Recombinant Plasma Proteins Revenue and Market Share by Type (2014-2019)

10.2 Global Recombinant Plasma Proteins Market Forecast by Type (2019-2024)

10.3 Chinese Hamster Ovary (CHO) Cell Line Revenue Growth Rate (2014-2024)

10.4 Baby Hamster Kidney (BHK) Cell Line Revenue Growth Rate (2014-2024)

10.5 Human Embryonic Kidney (HEK) Cell Line Revenue Growth Rate (2014-2024)

10.6 Others Revenue Growth Rate (2014-2024)

11 Global Recombinant Plasma Proteins Market Segment by Application

11.1 Global Recombinant Plasma Proteins Revenue Market Share by Application (2014-2019)

11.2 Recombinant Plasma Proteins Market Forecast by Application (2019-2024)

11.3 Hemophilia A Revenue Growth (2014-2019)

11.4 Hemophilia B Revenue Growth (2014-2019)

11.5 Von Willebrand Disease Revenue Growth (2014-2019)

11.6 Others Revenue Growth (2014-2019)

12 Global Recombinant Plasma Proteins Market Size Forecast (2019-2024)

12.1 Global Recombinant Plasma Proteins Market Size Forecast (2019-2024)

12.2 Global Recombinant Plasma Proteins Market Forecast by Regions (2019-2024)

12.3 North America Recombinant Plasma Proteins Revenue Market Forecast (2019-2024)

12.4 Europe Recombinant Plasma Proteins Revenue Market Forecast (2019-2024)

12.5 Asia-Pacific Recombinant Plasma Proteins Revenue Market Forecast (2019-2024)

12.6 South America Recombinant Plasma Proteins Revenue Market Forecast (2019-2024)

12.7 Middle East and Africa Recombinant Plasma Proteins Revenue Market Forecast (2019-2024)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Recombinant Plasma Proteins Picture

Table Product Specifications of Recombinant Plasma Proteins

Table Global Recombinant Plasma Proteins and Revenue (Million USD) Ma